Vitamin K supplementation and vascular calcification in people with type 2 diabetes and chronic kidney disease: a randomized controlled trial
Zwakenberg SR, de Jong PA, Bartstra JW, van Asperen R, Westerink J, de Valk H
Published in American Journal of Clinical Nutrition
Methodology
Six-month randomised, double-blind, placebo-controlled trial of menaquinone-7 360 mcg/day in 68 adults with type 2 diabetes and chronic kidney disease, with CT calcification imaging.
Key Findings
Vitamin K status improved markedly but there was no difference in femoral artery or coronary calcification progression versus placebo.
Conclusions
Six months of MK-7 did not reduce vascular calcification in this high-risk population.
Limitations
Small sample and short duration relative to calcification progression rates.
Supplements Studied
Six months of MK-7 did not reduce femoral or coronary artery calcification despite improved vitamin K status.
Vitamin K status improved markedly but there was no difference in femoral artery or coronary calcification progression versus placebo.
Outcomes Measured
Vascular calcification progression was unchanged despite markedly improved vitamin K status.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.